CD45 expression in low-grade B-cell non-Hodgkin's lymphomas

Carulli, Giovanni; Cannizzo, Elisa; Zucca, Alessandra; Buda, Gabriele; Orciuolo, Enrico; Marini, Alessandra; Petrini, Mario

doi:10.1016/j.leukres.2007.06.002

« Previous Next »Leukemia Research
Volume 32, Issue 2 , Pages 263-267, February 2008

CD45 expression in low-grade B-cell non-Hodgkin's lymphomas

Giovanni Carulli
- Division of Hematology, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Italy
- Corresponding author at: Division of Hematology, Santa Chiara Hospital, Via Roma 67, I-56126 Pisa, Italy. Tel.: +39 050 992185; fax: +39 050 992185.
Elisa Cannizzo
- Division of Hematology, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Italy
Alessandra Zucca
- Division of Hematology, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Italy
Gabriele Buda
- Division of Hematology, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Italy
Enrico Orciuolo
- Division of Hematology, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Italy
Alessandra Marini
- Laboratory of Clinical Pathology, Section of Flow Cytometry, Ospedale Unico della Versilia, Lido di Camaiore, Italy
Mario Petrini
- Division of Hematology, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Italy

Received 8 April 2007; received in revised form 7 June 2007; accepted 12 June 2007. published online 07 March 2011.

Abstract

CD45 is a glycoprotein expressed in all lymphohemopoietic cells. Its expression increases during B-lymphocyte ontogeny. Few data are available about CD45 expression in the various types of low-grade B-cell non-Hodgkin's lymphomas (NHL). Low levels of CD45 have been reported in pathologic lymphocytes from typical chronic lymphocytic leukemia (CLL) and higher levels of this antigen have been observed in some cases of atypical CLL and in some cases of other types of NHL.

One hundred and seven bone marrow samples of NHL with bone marrow infiltration were investigated: 45 typical CLL, 15 atypical CLL, 9 mantle cell lymphomas (MCL), 1 MCL with CD23 expression, 18 marginal zone lymphomas (MZL), 6 lymphoplasmacytic lymphomas (LPL), 6 follicular lymphomas (FL), and 7 hairy cell leukemias (HCL).

CD45 expression was evaluated by flow cytometry: pathologic lymphocytes were identified on the basis of specific immunophenotypic profile, CD19/K or CD19/λ co-expression. Results were expressed as median fluorescence intensity (MFI) along a 1024 linear scale. CD45 expression was measured also on autologous T-lymphocytes and a “CD45 index” was calculated as the ratio MFI of pathologic B-lymphocytes/MFI of T-lymphocytes, to normalize the results obtained.

We found four CD45 expression patterns: very low in typical CLL; relatively low in MCL; intermediate intensity in MZL, LPL, and FL; very high expression in HCL. Among the atypical cases, very high CD45 expression was found in one case of CD23-negative CLL, in CD23-positive MCL, and CLL with atypical morphology.

The results indicate different levels of maturation in low-grade NHL and may help to characterize such neoplasias.

Keywords: Atypical CLL, CLL, CD45, Flow cytometry, Non-Hodgkin's lymphomas